This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.

Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332

The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder

There are currently 32 open trials. In 128 locations

What is a Clinical Trial?

Step 2: Choose a Trial

There are currently 32 open trials

Step 3: View Details

Trial Title:

Daratumumab with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients

Treatments:

Daratumumab (Darzalex®)
Bortezomib (Velcade®)
Lenalidomide (Revlimid)
Dexamethasone

Myeloma stage:

Newly Diagnosed

Trial phase:

III

Summary

Summary:

This trial is determining whether daratumumab plus bortezomib, lenalidomide and dexamethasone is more effective than bortezomib, lenalidomide and dexamethasone alone for the treatment of newly diagnosed myeloma patients not receiving high-dose therapy and stem cell transplant (HD-SCT).

The trial hopes to show D-VRd improves overall minimal residual disease (MRD) negativity rate compared with VRd alone.

Locations

Locations:

North Manchester General Hospital, Manchester

Who can enter the study?

Who can enter the study?:

Newly diagnosed myeloma patients not receiving  HD-SCT as initial treatment.

What's involved?

What's involved?:

Patients will be randomised to receive either daratumumab plus bortezomib, lenalidomide (D-VRd) and dexamethasone or bortezomib, lenalidomide and dexamethasone (VRd).

For patients assigned to VRd:

  • Bortezomib, lenalidomide and dexamethasone will be given in 21 day cycles for the first 8 cycles. Followed by lenalidomide and dexamethasone in 28 cycles until disease progression or treatment is stopped for other reasons.
  • Bortezomib will be given subcutaneously (injection under the skin), lenalidomide and dexamethasone will be given orally.

For patients assigned to D-VRd:

  • Daratumumab, bortezomib, lenalidomide and dexamethasone will be given in 21 day cycles for the first 8 cycles. Followed by daratumumab, lenalidomide and dexamethasone in 28 cycles until disease progression or treatment is stopped for other reasons.
  • Daratumumab and bortezomib will be given subcutaneously (injection under the skin), lenalidomide and dexamethasone will be given orally.

Patients are required to attend outpatient clinics for regular check-ups and tests. Test will include bone marrow biopsies, blood tests, skeletal surveys and electrocardiograms (EGC).

Duration of the trial is approximately 6.5 years.

 

Clinical Information

Clinical Information
(for Medical Professionals):

This trial is evaluating the safety and efficacy of daratumumab plus bortezomib, lenalidomide and dexamethasone is more effective than bortezomib, lenalidomide and dexamethasone alone for the treatment of newly diagnosed  myeloma patients for whom HD-SCT is not planned as initial therapy.

The trial hopes to demonstrate that D-VRd improves overall MRD negativity rate compared with VRd alone. It will also evaluate PFS, OS, durable MRD negative rates, response duration and response rates.

For more information, click here.

Do you want to talk to someone? Call our myeloma Infoline